Ingrezza for Tardive Dyskinesia: Its Safety, Efficacy, and Implication


Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

Laxman Bahroo, DO, director of the Botulinum Toxin Clinic and associate professor of Neurology at Georgetown University Hospital, took time out of the 21st International Congress of Parkinson's Disease and Movement Disorders to discuss Ingrezza, the first and only treatment approved for Tardive Dyskinesia.

Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Elizabeth Aby, MD | Credit: Minnesota Health Fairview
Prashant Singh, MD | Credit: University of Michigan
Noa Krugliak Cleveland, MD | Credit: University of Chicago
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Ali Rezaie, MD | Credit: X
Should We Reclassify Diabetes Subtypes?
Remo Panaccione, MD | Credit: University of Calgary
Francisca Joly, MD, PhD | Credit: The Transplantation Society
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
© 2024 MJH Life Sciences

All rights reserved.